Medicare Advantage–pharmacy partnership improves influenza and pneumococcal vaccination rates

• DOI: 10.37765/ajmc.2021.88760
• Publication Date: 2021-10-19T20:51:05Z
• Authors: David P. Nau
• Keywords: Pharmacies; Vaccination; Community Pharmacy Services; Pharmacy; United States; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Influenza, Human; Humans; Medicare Part C; Female; Aged

To evaluate the impact of a collaborative effort Medicare Advantage and prescription drug (MAPD) plan community pharmacies to improve vaccination rates for pneumonia influenza.This quasiexperimental, cluster-randomized intervention study used MAPD data assess pharmacists on rates. Pharmacies in specific regions (districts) were randomly assigned or control groups. Intervention received reports patients with gap influenza (aged 19-89 years) and/or pneumococcal 65-89 vaccinations based medical pharmacy claims history. Vaccine-naïve offered vaccinations.The previously vaccine-naïve utilizing compared 6 months post randomization. Inverse probability weighted hierarchical generalized linear models determined odds receiving groups, controlling baseline clinical demographic characteristics.Intervention groups had similar ages older-adult cohort (mean age, 73.0 vs 73.4 years, respectively; P = .1255). The group was older than 67.7 66.4 .0006). Slightly more half each women, proportion women not significantly different between cohort. In multivariable analyses, associated higher delivering (odds ratio [OR], 1.91; 95% CI, 1.26-2.87) (OR, 2.18; 1.37-3.46) pharmacies.A health plan-enabled, pharmacist-led effective increasing number adults individuals vaccination.